Magic mushrooms, long considered sacred by the Indigenous Mazatec in Mexico, become the subject of scientific studies measuring the intense effects of its Psilocybin and its potential therapeutic use. In the second episode, we are introduced to Ben, who’s battled with crippling Obsessive-Compulsive Disorder (OCD) his entire life. When he had his firstborn, Ben’s life became full of panic attacks regarding his son’s safety, and he knew something had to change. Ben signed up for a psilocybin-assisted therapy clinical trial which was testing whether the psychedelic could help people with severe OCD. In the session under the influence of psilocybin, Ben felt decomposed and eventually grew into a tree. While living as a tree, he saw his human self, playing with his child. Though this sounds scary, from Ben’s perspective, it was beautiful. He was one with the universe, seeing himself in the ultimate third-person perspective. Finally, he saw how it could be different if he didn’t let his OCD control him. And several months out, all the symptoms disappeared. Ben’s story is one of many told in this series, which gives hope that help is right around the corner for the millions who suffer —often in silence— with debilitating mental disorders. But Michael Pollan’s work is showcasing the success stories. Often, even in the most successful trials, psychedelic-assisted therapy only helps up to a third of people enter remission. More frequently, patients are helped —sometimes substantially— but they still suffer with their illnesses and some people aren’t helped at all.
A ground-breaking new trial at Imperial College London sees, for the first time ever under controlled conditions, a psychedelic drug tested head-to-head against a standard antidepressant as a treatment for depression. The film follows a pioneering team of scientists and psychotherapists as they compare the effects of psilocybin (the active ingredient of magic mushrooms) with an antidepressant on a small group of participants with clinical depression. This is scientific research at its most cutting edge. With over seven million people being prescribed antidepressants each year in England alone, this drug trial is an important milestone in understanding a completely different treatment for depression. How do psychedelic drugs measure up against the industry-standard antidepressants that have been popular since the 1990s? The empirical results of the trial are explored alongside the participants’ powerful lived experience.
In the second episode, we are introduced to Ben, who’s battled with crippling Obsessive-Compulsive Disorder (OCD) his entire life. When he had his firstborn, Ben’s life became full of panic attacks regarding his son’s safety, and he knew something had to change. Ben signed up for a psilocybin-assisted therapy clinical trial which was testing whether the psychedelic could help people with severe OCD. In the session under the influence of psilocybin, Ben felt decomposed and eventually grew into a tree. While living as a tree, he saw his human self, playing with his child. Though this sounds scary, from Ben’s perspective, it was beautiful. He was one with the universe, seeing himself in the ultimate third-person perspective. Finally, he saw how it could be different if he didn’t let his OCD control him. And several months out, all the symptoms disappeared.
Ben’s story is one of many told in this series, which gives hope that help is right around the corner for the millions who suffer —often in silence— with debilitating mental disorders. But Michael Pollan’s work is showcasing the success stories. Often, even in the most successful trials, psychedelic-assisted therapy only helps up to a third of people enter remission. More frequently, patients are helped —sometimes substantially— but they still suffer with their illnesses and some people aren’t helped at all.